CHDI Foundation, Inc. and Siena Biotech SpA enter collaboration to validate novel therapeutic targets for Huntington’s disease
New York City, NY & Siena, Italy – CHDI Foundation, Inc. (CHDI) and Siena Biotech SpA have announced a collaboration to explore and validate molecular targets that could have therapeutic potential in Huntington’s disease (HD). CHDI, a not-for-profit research organization that is exclusively dedicated to rapidly discovering and developing therapies that slow the progression of HD, will partner equally with Siena Biotech, an innovative drug discovery company whose primary focus is on degenerative and proliferative diseases of the central nervous system, including HD, with the aim of discovering new drugs for therapeutic intervention.
“Siena Biotech is already committed to Huntington’s disease as a fundamental part of their portfolio, and we’re very excited to be able to draw on their neurological drug development expertise and their state-of-the-art laboratory infrastructure,” said Robert Pacifici, Chief Scientific Officer of CHDI. “Our new collaboration will initially focus on validating potential therapeutic targets that modulate post-translational modification of mutant huntingtin, and we hope this will mature into a full-fledged joint drug discovery program.”
“Our collaboration with CHDI will create a synergy between our two organization’s strengths that will accelerate progress towards our common goal of developing new therapies for Huntington’s disease, an objective to which both Siena Biotech and CHDI are fully dedicated” said Giovanni Gaviraghi, Chief Executive Officer of Siena Biotech.
About CHDI Foundation, Inc.
CHDI Foundation, Inc. is a privately-funded, not-for-profit, scientific organization exclusively dedicated to rapidly discovering and developing therapies that slow the progression of Huntington’s disease. As a collaborative enabler, CHDI seeks to bring the right partners together to identify and address critical scientific issues and move drug candidates to clinical evaluation as quickly as possible. Our scientists work closely with a network of more than 600 researchers in academic and industrial laboratories around the world in the pursuit of these novel therapies, providing project management to ensure that our common goals remain in focus.
More information about CHDI can be found at www.chdifoundation.org.
About Siena Biotech SpA
Siena Biotech SpA is an innovative, clinical-stage drug discovery company whose R&D efforts are focused on discovering new drugs for therapeutic intervention against neurodegenerative diseases and oncology. The company, based in Siena, Italy, is structured around drug discovery technology platforms from target validation to clinical studies. The company has developed an internal portfolio of several innovative R&D projects in three therapeutic areas: Alzheimer’s disease, Huntington’s disease and cancer. The projects are rapidly progressing through the pipeline, in some cases as parts of strategic R&D alliances with major pharmaceutical companies. Siena Biotech has built a wide network of external collaborations, both in the academic and business communities, to add to the scientific excellence of internal R&D, thus creating a sound scientific base for its interactions with patients and physicians. Siena Biotech is the instrumental company of the Monte dei Paschi di Siena Foundation to operate in the field of scientific research and biotechnology, in line with its founding charter and mission.
More information about Siena Biotech can be found at www.sienabiotech.com.
More information is also available from
|Simon Noble||Barbara Silvestri|
|Director, Scientific Communications||Executive Assistant & Communications – CEO Office|
|CHDI Management/CHDI Foundation||Siena Biotech SpA|
|+1 212 660 8112||+39 0577 381205|